文献速递骨质疏松与代谢性骨病

地舒单抗与恶性肿瘤风险无关:随机对照试验的系统综述与荟萃分析

Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Osteoporos Int · 2020-11-03

该荟萃分析纳入25项随机对照试验共21523例患者,评估地舒单抗(每6个月60 mg,最长48个月)与任何对照相比的恶性肿瘤风险。结果显示两组恶性肿瘤风险相似(绝对风险差0%,RR 1.08,95%CI 0.93-1.24,I2=0%),亚组分析和恶性肿瘤相关死亡风险也无差异。

要点

  • 地舒单抗每6个月60 mg治疗与对照组恶性肿瘤风险相似,RR 1.08(95%CI 0.93-1.24)。
  • 按种族、对照类型、适应症及暴露≥24个月分层,恶性肿瘤风险均无差异。
  • 恶性肿瘤相关死亡风险两组相似,早期免疫调节担忧未获证据支持。

核心结论

  • 地舒单抗治疗与恶性肿瘤风险增加无关,绝对风险差0%,RR 1.08(95%CI 0.93-1.24)。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Cochrane Central Register of Controlled Trials至2019年5月27日,纳入25项随机对照试验共21523例患者。

主要发现

  • 地舒单抗与其他对照的恶性肿瘤风险相似,绝对风险差0%,RR 1.08(95%CI 0.93-1.24),I2=0%。
  • 基于充分分配隐藏的敏感性分析结果相似。
  • 按种族、个体对照、治疗适应症及较长药物暴露(≥24个月,9项研究)分层的亚组分析中,恶性肿瘤风险均无差异。
  • 恶性肿瘤相关死亡的风险比两组相似。

关键数值与推荐

  • 纳入标准为地舒单抗(每6个月60 mg)对比任何对照的随机对照试验,排除使用更高剂量预防骨相关事件的试验。
  • 药物暴露最长48个月。

临床怎么用

  • 对于接受地舒单抗每6个月60 mg治疗的患者,无需因恶性肿瘤风险担忧而改变临床决策,但仍需通过上市后监测发现罕见或迟发事件。

局限性

  • 随机对照试验对安全性结局的观察时间有限,罕见或迟发事件需依赖上市后监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The immunomodulatory effects of denosumab have raised concerns for risk of malignancy. This meta-analysis of 25 randomized controlled trials (21,523 patients) shows similar risk of malignancy between denosumab (60 mg every 6 months, up to 48 months) and any comparator. Post-marketing surveillance may detect rare or late-occurring drug effects. Possible increased risk of malignancy in patients treated with denosumab has been concerned due to inhibition of the immune modulator receptor activator of nuclear factor κ-Β ligand (RANKL). We aimed to assess the risk of malignancy associated with denosumab treatment. PubMed and Cochrane Central Register of Controlled Trials were searched up to May 27, 2019 to include all randomized controlled trials of denosumab (60 mg every 6 months) versus any comparator. Trials using higher drug doses for prevention of skeletal-related events were excluded. Data were independently extracted by two reviewers and analyzed using a fixed-effect model to pool risk ratios (RRs) with 95% confidence intervals (CI). Twenty-five trials (21,523 patients) were included. The risk of malignancy was similar between denosumab and other comparators (absolute risk difference 0%, RR 1.08 [95% CI, 0.93-1.24], I2 = 0%). Sensitivity analysis based on adequate allocation concealment showed similar results. The risk of malignancy did not differ between groups in any of the subgroup analyses, including stratification by race, individual comparators, indications for treatment, and longer drug exposure (≥ 24 months, 9 studies). The risk ratio of malignancy-related death was similar between groups. Early concerns about a potential increased risk of malignancy resulting from an immunomodulatory effect of denosumab are not supported by evidence from this meta-analysis of 25 RCTs with drug exposure of up to 48 months. Since RCTs with longer observation for safety outcomes are not expected, post-marketing surveillance will be the main means for detection of rare or late-occurring events.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Rosenberg D, Avni T, Tsvetov G, et al. Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2020. PMID: 33145606. doi:10.1007/s00198-020-05704-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。